4.5 Article

A novel short splice variant of the tumour suppressor LKB1 is required for spermiogenesis

期刊

BIOCHEMICAL JOURNAL
卷 416, 期 -, 页码 1-14

出版社

PORTLAND PRESS LTD
DOI: 10.1042/BJ20081447

关键词

AMP-activated protein kinase (AMPK); LKB1; male fertility; spermiogenesis; splice variants

资金

  1. Wellcome Trust [809821]
  2. Cancer Research U.K [C347/A83631]
  3. European Commission [LSHM-CT-2004005272]
  4. AstraZeneca
  5. Boehringer-ingelheim
  6. GlaxoSmithKIine
  7. Merck Co
  8. Merck KGaA
  9. Pfizer
  10. Medical Research Council [MC_U127088492] Funding Source: researchfish
  11. MRC [MC_U127088492] Funding Source: UKRI

向作者/读者索取更多资源

LKB1 was discovered as a tumour suppressor mutated in Peutz-Jeghers syndrome, and is a gene involved in cell polarity as well as an upstream protein kinase for members of the AMP-activated protein kinase family. We report that mammals express two splice variants caused by alternate usage of 3'-exons. LKB1(L) is the previously described form, while LKB1(S) is a novel form in which the last 63 residues are replaced by a unique 39-residue sequence lacking known phosphorylation (Ser(431)) and farnesylation (Cys(433)) sites. Both isoforms are widely expressed in rodent and human tissues, although LKB1(S) is particularly abundant in haploid spermatids in the testis. Male mice in which expression of Lkb1(S) is knocked out are sterile, with the number of mature spermatozoa in the epididymis being dramatically reduced, and those spermatozoa that are produced have heads with an abnormal morphology and are non-motile. These results identify a previously undetected variant of LKB1, and suggest that it has a crucial role in spermiogenesis and male fertility.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据